Bacil Pharma MD, chairman, board of directors and AGM
BSE: 524516Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹20.44.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹29 Cr3,172nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 Oct 2026
- 1.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Oct 2026
- −0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 14 Oct 2026
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day.
- 5,940
Bacil Pharma board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonCHAITALI KALPATARU SHAH
5 directors3 independent2 executive
- CHAITALI KALPATARU SHAH · ChairpersonExecutive · joined Sep 2025 · 15 months as independent · 1 listed board · 1 committee seat, 1 as chair
- OMPRAKASH PYARELAL SONARIndependent · joined Jun 2026 · 3 months as independent · 1 listed board · 1 as independent
- VIVEK MUKESH YADAVIndependent · joined Jun 2026 · 3 months as independent · 1 listed board · 1 as independent · 1 committee seat
- MAHESH SINGHIndependent · joined Aug 2026 · 1 month as independent · 1 listed board · 1 as independent
- ANIL SHIV CHARAN SINGHExecutive · joined Aug 2026 · 1 month as independent · 1 listed board · 1 as independent
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
3 directors who left
- AVANI SAVJIBHAI GODHANIYA, left 9 Jul 2026: Others
- DINESH CHANDER NOTIYAL, left 9 Jul 2026: Others
- PRAKASH BHOORCHAND SHAH, left 22 Jul 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 29 Aug 20264 of 4 present3 independent · 3 days in between
- 25 Aug 20264 of 4 present3 independent · 12 days in between
- 12 Aug 20264 of 4 present3 independent · 33 days in between
- 9 Jul 20264 of 4 present3 independent · 12 days in between
2 earlier meetings
- 26 Jun 20263 of 3 present2 independent · 34 days in between
- 22 May 20263 of 3 present2 independent
Audit Committee
Chair VIVEK MUKESH YADAV
CHAITALI KALPATARU SHAH, OMPRAKASH PYARELAL SONAR, MAHESH SINGH
- 12 Aug 20264 of 4 present3 independent · 81 days in between
- 22 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair VIVEK MUKESH YADAV
CHAITALI KALPATARU SHAH, OMPRAKASH PYARELAL SONAR, MAHESH SINGH
- 25 Aug 20264 of 4 present3 independent · 12 days in between
- 12 Aug 20264 of 4 present3 independent · 81 days in between
- 22 May 20263 of 3 present2 independent
Stakeholders Relationship Committee
Chair VIVEK MUKESH YADAV
CHAITALI KALPATARU SHAH, OMPRAKASH PYARELAL SONAR, MAHESH SINGH
- 12 Aug 20264 of 4 present3 independent · 81 days in between
- 22 May 20263 of 3 present2 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Jun 2026.
- Sarang Shivajirao Chavan and AssociatesPeer-review certificate valid to Jun 2028
1 earlier auditor
- Laxmikant Kabra & Co LLPNamed in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Bacil Pharma AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Bacil Pharma share news and announcements
Annual general meeting, 23 Sep 2026
7,703 shareholders on the register on 18 Sep 2026; present: 0 promoters and 66 others; votes counted by RAMESH CHANDRA BAGDI / RAMESH CHANDRA BAGDI & ASSOCIATES.The company's voting result (opens in a new tab)
To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2026, including the Audited Balance Sheet as at March 31, 2026, the Statement of Profit and Loss & Cash Flow Statement for the Year ended on that date together with the Reports of the Board of Directors and Auditors there onMoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 37.62% · promoters 0.00% · institutions 0.00% · other public 37.62%
- To appoint a Director in place of Ms. Chaitali Kalpataru Shah (DIN: 11167778), who retires by rotation at this Annual General Meeting and being eligible, offers herself for re-appointmentOrdinary99.93% for0.07% against
Against: promoters 0.00% · institutions 0.00% · other public 0.07%
Turnout: all 37.62% · promoters 0.00% · institutions 0.00% · other public 37.62%
- Change in Designation of Ms. Chaitali Kalpataru Shah (DIN: 11167778) from Executive Director to Managing Director of the CompanySpecial99.93% for0.07% against
Against: promoters 0.00% · institutions 0.00% · other public 0.07%
Turnout: all 37.62% · promoters 0.00% · institutions 0.00% · other public 37.62%
- Re-appointment of Mr. Omprakash Pyarelal Sonar (DIN: 11031877) as Non - Executive Independent Director of the CompanySpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 37.62% · promoters 0.00% · institutions 0.00% · other public 37.62%
- Re-appointment of Mr. Vivek Mukesh Yadav (DIN: 11033957) as Non - Executive Independent Director of the CompanySpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 37.62% · promoters 0.00% · institutions 0.00% · other public 37.62%
- To appoint M/s Sarang Shivajirao Chavan & Associates Chartered Accountants (FRN: 159649W) as Statutory Auditors of the Company and fix their remunerationSpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 37.62% · promoters 0.00% · institutions 0.00% · other public 37.62%
- Increase in Authorised Share Capital of the Company and alteration of capital clause of memorandum of association of the companyOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 37.62% · promoters 0.00% · institutions 0.00% · other public 37.62%
- Re-appointment of Mr. Mahesh Singh (DIN: 11814569) as Non - Executive Independent Director of the CompanySpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 37.62% · promoters 0.00% · institutions 0.00% · other public 37.62%
- Re-appointment of Mr. Anil Singh (DIN: 09338444) as Non - Executive Non-Independent Director of the CompanySpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 37.62% · promoters 0.00% · institutions 0.00% · other public 37.62%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.